Search Results

16 Bit Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted a De Novo marketing authorization for Rho™, an AI-enabled software device aimed at improving a known care gap in osteoporosis screening.

Tonix Pharmaceuticals Holding Corp. today announced that it has engaged Rho, Inc. (Rho), a global contract research organization (CRO), to support Tonix’s preparation and planned submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia.

Ocugen, Inc. today announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations.

Rho, a full-service contract research organization with a proven track record of drug development success, announced the appointment of J. Marc Pipas, MD, a leading oncologist, as Senior Medical Director.

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”) announced today that it has entered into an agreement with Rho, a full-service contract research organization (CRO), for its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase.